The data revealed that activation of KRAS and loss of TP53 in an alveolar type 2 (AT2) cell initiate tumor formation through a transient increase in cellular plasticity, involving gastric-like or lung-mixed states followed by EMT-associated intermediates, before subclones capable of metastasizing arise (131). This evidence concerns the gene KRAS and neoplasm.